Skip to main content
Fig. 10 | Molecular Neurodegeneration

Fig. 10

From: Autoimmune antibody decline in Parkinson’s disease and Multiple System Atrophy; a step towards immunotherapeutic strategies

Fig. 10

Cross-binding competition ELISA assays. a, b, and c: The two site inhibition curves show distinct high and low binding components in plasma from Parkinson’s Disease (PD-blue, squares), Multiple System Atrophy (MSA-green, triangles) patients and normal control (NC-black, circles) subjects. Ten plasma samples from each group were pooled and incubated in 1:400 dilution with increasing concentration of α-, β-, and γ-synuclein monomers in combinations as indicated, with subsequent measurement of free NAbs by ELISA on plates coated with 10 μg/ml of α-synuclein. d-i: Percentage of inhibition (PI) of individual plasma samples with free d, e: α−/β-synuclein monomers, F, G: α−/γ-synuclein monomers; h, i: β−/γ-synuclein monomer on plates coated with 10 μg/mL of α-synuclein monomer. Plasma samples from Parkinson’s Disease (PD), Multiple System Atrophy (MSA) patients and normal controls (NC) were tested at 1:400 dilution in the presence of (d, f, h) 100 nM or (e, g, i) 10 nM α-, β-, and γ-synuclein monomers in combinations. Horizontal bars represent the mean values +/− SEM. Significance was tested using Man–Whitney’s U test (P < 0.05)

Back to article page
\